CLINICAL TRIALS PROFILE FOR SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES
✉ Email this page to a colleague
All Clinical Trials for SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03040323 ↗ | Prospective Analysis of Value of Contrast-enhanced Sonography During Biopsies of Focal Liver Masses | Terminated | Indiana University | Phase 4 | 2016-12-22 | The investigators plan to compare complication and success rates between two methods of ultrasound guidance for biopsy of liver lesions, contrast-enhanced and the current protocol without contrast. |
| NCT03300401 ↗ | Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 Radioembolization | Withdrawn | National Cancer Institute (NCI) | N/A | 2017-11-07 | This pilot clinical trial studies how well contrast-enhanced ultrasound in diagnosing patients with liver cancer who are undergoing Yttrium-90 radioembolization. Contrast-enhanced ultrasound may provide detailed imaging of the tumor arteries after the injection of a contrast-agent consisting of microbubbles, and may predict how much Yttrium-90 will deposit in the tumor. |
| NCT03300401 ↗ | Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 Radioembolization | Withdrawn | University of Southern California | N/A | 2017-11-07 | This pilot clinical trial studies how well contrast-enhanced ultrasound in diagnosing patients with liver cancer who are undergoing Yttrium-90 radioembolization. Contrast-enhanced ultrasound may provide detailed imaging of the tumor arteries after the injection of a contrast-agent consisting of microbubbles, and may predict how much Yttrium-90 will deposit in the tumor. |
| NCT03407001 ↗ | Contrast Enhanced Ultrasound With Lumason in Detecting Liver Cancer in Participants With Cirrhosis | Completed | National Cancer Institute (NCI) | Early Phase 1 | 2018-01-12 | This early phase I trial studies how well contrast enhanced ultrasound with sulfur hexafluoride lipid microspheres (Lumason) works in detecting liver cancer in participants with cirrhosis. Contrast enhanced-ultrasounds use contrast agents, such as Lumason, that are injected into a vein in order to help certain organs and tissues show up more clearly on scans. Contrast enhanced ultrasound with Lumason may help doctors more easily find liver cancer compared to ultrasounds without contrast agent. |
| NCT03407001 ↗ | Contrast Enhanced Ultrasound With Lumason in Detecting Liver Cancer in Participants With Cirrhosis | Completed | M.D. Anderson Cancer Center | Early Phase 1 | 2018-01-12 | This early phase I trial studies how well contrast enhanced ultrasound with sulfur hexafluoride lipid microspheres (Lumason) works in detecting liver cancer in participants with cirrhosis. Contrast enhanced-ultrasounds use contrast agents, such as Lumason, that are injected into a vein in order to help certain organs and tissues show up more clearly on scans. Contrast enhanced ultrasound with Lumason may help doctors more easily find liver cancer compared to ultrasounds without contrast agent. |
| NCT03549507 ↗ | CEUS Evaluation of Bowel Perfusion in Necrotizing Enterocolitis | Recruiting | Bracco Diagnostics, Inc | Phase 3 | 2020-11-04 | There is no bedside imaging technique that can quantify dynamic bowel perfusion with high soft tissue contrast and sensitivity in necrotizing enterocolitis (NEC). Our goal is to assess the feasibility of utilizing contrast-enhanced ultrasound (CEUS) in bedside monitoring of bowel perfusion in NEC. Patients with suspected or diagnosed NEC will be recruited for the study. Following parental consent, the subject will undergo CEUS, performed separately from any clinically indicated conventional US, in the ICU. Subjects will be scanned with CEUS at two different time-points (at the time NEC is first suspected or diagnosed and at time of MRI scan). The CEUS scans will be interpreted by the sponsor-investigator. The study will be conducted at one site, The Children's Hospital of Philadelphia. It is expected that up to 100 subjects will be enrolled per year, for up to two years, for a total enrollment of up to 200 subjects. |
| NCT03549507 ↗ | CEUS Evaluation of Bowel Perfusion in Necrotizing Enterocolitis | Recruiting | Children's Hospital of Philadelphia | Phase 3 | 2020-11-04 | There is no bedside imaging technique that can quantify dynamic bowel perfusion with high soft tissue contrast and sensitivity in necrotizing enterocolitis (NEC). Our goal is to assess the feasibility of utilizing contrast-enhanced ultrasound (CEUS) in bedside monitoring of bowel perfusion in NEC. Patients with suspected or diagnosed NEC will be recruited for the study. Following parental consent, the subject will undergo CEUS, performed separately from any clinically indicated conventional US, in the ICU. Subjects will be scanned with CEUS at two different time-points (at the time NEC is first suspected or diagnosed and at time of MRI scan). The CEUS scans will be interpreted by the sponsor-investigator. The study will be conducted at one site, The Children's Hospital of Philadelphia. It is expected that up to 100 subjects will be enrolled per year, for up to two years, for a total enrollment of up to 200 subjects. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES
Condition Name
Clinical Trial Locations for SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES
Trials by Country
Clinical Trial Progress for SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES
Clinical Trial Phase
Clinical Trial Sponsors for SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES
Sponsor Name
